riociguat for PAH
Selected indexed studies
- Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. (JAMA, 2022) [PMID:35412560]
- Pulmonary Hypertension: A Brief Guide for Clinicians. (Mayo Clin Proc, 2020) [PMID:32861339]
- Update of EULAR recommendations for the treatment of systemic sclerosis. (Ann Rheum Dis, 2017) [PMID:27941129]
_Worker-drafted node — pending editorial review._
Connections
riociguat for PAH is a side effect of
Sources
- Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. (2022) pubmed
- Pulmonary Hypertension: A Brief Guide for Clinicians. (2020) pubmed
- Update of EULAR recommendations for the treatment of systemic sclerosis. (2017) pubmed
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis. (2024) pubmed
- New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025. (2025) pubmed
- New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. (2024) pubmed
- The role of riociguat in combination therapies for pulmonary arterial hypertension. (2023) pubmed
- EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH. (2019) pubmed
- Riociguat for the treatment of pulmonary hypertension: a safety evaluation. (2016) pubmed
- Riociguat for the treatment of pulmonary hypertension. (2014) pubmed